【摘要】 目的探究西格列汀联合二甲双胍治疗2型糖尿病的临床效果。方法采用随机数字表法将随机选取2017年11月—2019年8月该院收治入院及门诊治疗的80例2型糖尿病患者分为观察组和(40例)对照组(40例),对照组采用盐酸二甲双胍片治疗,观察组在上述基础上加用磷酸西格列汀片,比较两组患者治疗前后体重指数(BMI)、血糖[空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)]水平、生活质量评分及不良反应发生情况。结果两组患者治疗前后BMI及FPG、2 hPG、HbA1c水平均显著变化,且观察组治疗后上述指标均显著低于对照组,差异有统计学意义(P<0.05)。两组患者治疗前后A-DQOL评分各个维度及总分均显著降低,且观察组治疗后上述评分显著低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率5.0%显著低于对照组20.0%,差异有统计学意义(χ~2=4.114,P<0.05)。结论西格列汀联合二甲双胍治疗2型糖尿病可显著改善患者血糖水平,提升生活质量,不良反应少。更多还原

【Abstract】 Objective To explore the clinical effect of sitagliptin combined with metformin in the treatment of type 2 diabetes. Methods Using a random number table method, 80 patients with type 2 diabetes who were randomly selected and treated in the hospital from November 2017 to August 2019 were divided into observation group(40 cases) and control group(40 cases), the control group was treated with metformin hydrochloride tablets, and the observation group was treated with sitagliptin phosphate tablets on the above basis. The body mass index(BMI), blood glucose(fasting blood glucose(FPG), 2 h postprandial blood glucose(2 hPG), glycosylated hemoglobin(HbA1 c) levels, quality of life scores and adverse reactions were compared between the two groups before and after treatment. Results Compared with before treatment, the levels of BMI, FPG, 2 hPG and HbA1 c in the two groups were significantly changed after treatment, and the above indexes were significantly lower in the observation group than in the control group after treatment,the difference was statistically significant(P <0.05). Compared with before treatment, the A-DQOL scores in all dimensions and total scores of the two groups were significantly reduced after treatment, and the above scores in the observation group were significantly lower than those in the control group after treatment,the difference was statistically significant(P<0.05). The incidence of adverse reactions in the observation group 5.0% was significantly lower than the control group 20.0%,the difference was statistically significant(χ~2=4.114, P <0.05). Conclusion Sitagliptin combined with metformin in patients with type 2 diabetes can significantly improve blood glucose levels, improve quality of life, and have fewer adverse reactions.更多还原